MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

Not yet recruitingOBSERVATIONAL
Enrollment

1,143

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

August 5, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Gastric CancerGastroesophageal Junction AdenocarcinomaFruquintinibRamucirumab
Interventions
DRUG

Fruquintinib+Paclitaxel

(using IPD from the FRUTIGA trial, n=703) Fruquintinib:subjects received Fruquintinib orally, once daily for 3 wks on/ 1 wk off Paclitaxel:Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.

DRUG

Ramucirumab+Paclitaxel

(using published AgD from RAINBOW-Asia, n=440) Ramucirumab:8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel :Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.

All Listed Sponsors
lead

Sun Yat-sen University

OTHER